Palbociclib and endocrine therapy in fourth line and beyond for hormone receptor-positive HER2-negative advanced breast cancer: The UK compassionate access program experience

被引：0
|
作者：
Battisti, N. M. L.
Kingston, B.
King, J.
Denton, A.
Waters, S.
Sita-Lumsden, A.
Rehman, F.
Stavraka, C.
Kristeleit, H.
Sawyer, E.
Houghton, D.
Davidson, N.
Howell, S.
Choy, J.
Harper, P.
Roylance, R.
Fharat, R.
Mohammed, K.
Ring, A.
Johnston, S.
机构：
[1] Royal Marsden NHS Fdn Trust, London, England
[2] Royal Free London NHS Fdn Trust, London, England
[3] East & North Herts NHS Trust, Stevenage, Herts, England
[4] Velindre Canc Ctr, Cardiff, S Glam, Wales
[5] Imperial Coll Healthcare NHS Trust, London, England
[6] Guys & St Thomas NHS Fdn Trust, London, England
[7] Kings Coll London, Sch Canc & Pharmaceut Sci, London, England
[8] Ramsay Hlth Care UK Rivers Hosp, Sawbridgeworth, England
[9] Christie NHS Fdn Trust, Manchester, Lancs, England
[10] LOC Leaders Oncol Care, London, England
[11] Univ Coll London Hosp NHS Fdn Trust, London, England
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P6-18-23
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-18-23
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    Kahraman, Seda
    Erul, Enes
    Seyyar, Mustafa
    Gumusay, Ozge
    Bayram, Ertugrul
    Demirel, Burcin Cakan
    Acar, Omer
    Aksoy, Sercan
    Baytemur, Naziyet Kose
    Sahin, Elif
    Cabuk, Devrim
    Basaran, Gul
    Paydas, Semra
    Yaren, Arzu
    Guven, Deniz Can
    Erdogan, Atike Pinar
    Demirci, Umut
    Yasar, Alper
    Bayoglu, Ibrahim Vedat
    Hizal, Mutlu
    Gulbagci, Burcu
    Paksoy, Nail
    Davarci, Sena Ece
    Yilmaz, Funda
    Dogan, Ozlem
    Orhan, Sibel Oyucu
    Kayikcioglu, Erkan
    Aytac, Ali
    Keskinkilic, Merve
    Mocan, Eda Eylemer
    Unal, Olcun Umit
    Aydin, Esra
    Yucel, Hakan
    Isik, Deniz
    Eren, Onder
    Uluc, Basak Oyan
    Ozcelik, Melike
    Hacibekiroglu, Ilhan
    Aydiner, Adnan
    Demir, Hacer
    Oksuzoglu, Berna
    Cilbir, Ebru
    Cubukcu, Erdem
    Cetin, Bulent
    Oktay, Esin
    Erol, Cihan
    Okutur, Sadi Kerem
    Yildirim, Nilgun
    Alkan, Ali
    Selcukbiricik, Fatih
    FUTURE ONCOLOGY, 2023, : 727 - 736
  • [42] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
    Hugo Herrscher
    Michel Velten
    Julie Leblanc
    Michal Kalish-Weindling
    Cathie Fischbach
    Delphine Exinger
    Xavier Pivot
    Thierry Petit
    Breast Cancer Research and Treatment, 2020, 179 : 371 - 376
  • [43] A phase 2 open label study of everolimus in combination with endocrine therapy in resistant hormone receptor-positive HER2-negative advanced breast cancer
    Yardley, D. A.
    Blakely, L.
    Hemphill, B.
    Joseph, M.
    Liggett, W.
    Daniel, B.
    Castrellon, A.
    Shastry, M.
    Finney, L.
    DeBusk, L.
    Hainsworth, J. D.
    Burris, H. A., III
    CANCER RESEARCH, 2017, 77
  • [44] Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
    Pernas, Sonia
    Sanfeliu, Esther
    Villacampa, Guillermo
    Salvador, Javier
    Perello, Antonia
    Gonzalez, Xavier
    Jimenez, Begona
    Merino, Maria
    Palacios, Patricia
    Pascual, Tomas
    Alba, Emilio
    Villanueva, Lorea
    Chillara, Samyukta
    Ferrero-Cafiero, Juan Manuel
    Galvan, Patricia
    Prat, Aleix
    Ciruelos, Eva
    NPJ BREAST CANCER, 2024, 10 (01)
  • [45] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
    Herrscher, Hugo
    Velten, Michel
    Leblanc, Julie
    Kalish-Weindling, Michal
    Fischbach, Cathie
    Exinger, Delphine
    Pivot, Xavier
    Petit, Thierry
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (02) : 371 - 376
  • [46] FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Walker, Amanda J.
    Wedam, Suparna
    Amiri-Kordestani, Laleh
    Bloomquist, Erik
    Tang, Shengui
    Sridhara, Rajeshwari
    Chen, Wei
    Palmby, Todd R.
    Zirkelbach, Jeanne Fourie
    Fu, Wentao
    Liu, Qi
    Tilley, Amy
    Kim, Geoffrey
    Kluetz, Paul G.
    McKee, Amy E.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2016, 22 (20) : 4968 - 4972
  • [47] Current Management and Future Perspectives of Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
    Gilchrist, Jenny
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [48] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1176 - 1177
  • [49] Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer
    Rugo, Hope S.
    Haltner, Anja
    Zhan, Lin
    Tran, Anh
    Bananis, Eustratios
    Hooper, Becky
    Mitra, Debanjali
    Cameron, Chris
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (06) : 457 - 467
  • [50] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26): : 2557 - 2570
12345